Barron's on MarketWatch: Analysts see market as overreacting to Gilead news
Investors may be too enthusiastic about a scoop from the health-care news website STAT on a trial of Gilead Sciences’ antiviral drug remdesivir in patients with severe Covid-19, analysts say.
Gilead shares were up 10.6% shortly after the open on Friday, and had risen much further in trading after the close on Thursday. STAT reported Thursday evening that nearly all of the patients at one Chicago hospital participating in a Gilead-sponsored trial of remdesivir were discharged in less than a week.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Here's what happened to the stock market on WednesdayStocks were under pressure as dismal economic data and weak bank earnings dented market sentiment.
Read more »
Stock market live updates: Dow futures up, bracing for jobless claimsStocks are coming off a major sell-off on Tuesday from dismal earnings and economic data.
Read more »
Stock market faces a critical decision now, trader saysAre we in a bear market trap or are we going to new highs with the unprecedented economic stimulus package? strategist Todd Gordon takes a look.
Read more »
Big Gains in Havens Stoke Worries About Stock-Market PullbackSafer assets from gold to Treasurys are rising alongside major indexes, a sign that the stock market rebound hasn’t assuaged investors’ fears about the world economy.
Read more »
Here's what happened to the stock market on ThursdayWall Street grappled throughout the session with more concerns over the coronavirus outbreak and dismal economic data.
Read more »
US explores possibility that coronavirus started in Chinese lab, not a marketUS intelligence and national security officials say the United States government is looking into the possibility that the novel coronavirus originated in a Chinese laboratory rather than a market, according to multiple sources familiar with the matter who caution it is premature to draw any conclusions.
Read more »